# EDGAR Filing Document

**Accession Number:** 0001375088
**File Stem:** 0001415889-23-004103
**Filing Date:** 2023-3
**Character Count:** 9387
**Document Hash:** 9adb74f0e349b879908394409cb04557
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001415889-23-004103.hdr.sgml**: 20230303

**ACCESSION NUMBER**: 0001415889-23-004103

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20230301

**FILED AS OF DATE**: 20230303

**DATE AS OF CHANGE**: 20230303

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Vandervoort Adam C
- **CENTRAL INDEX KEY:** 0001375088

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37477
- **FILM NUMBER:** 23704236

**MAIL ADDRESS:**
- **STREET 1:** 485 MADISON AVENUE
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10022
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Teladoc Health, Inc.
- **CENTRAL INDEX KEY:** 0001477449
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-OFFICES & CLINICS OF DOCTORS OF MEDICINE [8011]
- **IRS NUMBER:** 043705970
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 2 MANHATTANVILLE ROAD
- **STREET 2:** SUITE 203
- **CITY:** PURCHASE
- **STATE:** NY
- **ZIP:** 10577
- **BUSINESS PHONE:** 2036352002

**MAIL ADDRESS:**
- **STREET 1:** 2 MANHATTANVILLE ROAD
- **STREET 2:** SUITE 203
- **CITY:** PURCHASE
- **STATE:** NY
- **ZIP:** 10577

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Teladoc, Inc.
- **DATE OF NAME CHANGE:** 20091123

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Vandervoort Adam C<br><sub>(Last) (First) (Middle)</sub><br>C/O TELADOC HEALTH, INC.,<br>2 MANHATTANVILLE ROAD, SUITE 203<br><sub>(Street)</sub><br>PURCHASE, NY 10577<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2023-03-01 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [ ] 10% Owner<br>[X] Officer (give title below) [ ] Other (specify below)<br>_CHIEF LEGAL OFFICER, SECRETARY_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Teladoc Health, Inc. [ TDOC ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Stock | 2023-03-01 |  | M |  | 7523 | A | <sup>(1)</sup> | 19506 | D |  |
| Common Stock | 2023-03-02 |  | S |  | 3877<sup>(2)</sup> | D | $25.362 | 15629 | D |  |
| Common Stock | 2023-03-02 |  | M |  | 1941 | A | <sup>(1)</sup> | 17570 | D |  |
| Common Stock | 2023-03-02 |  | M |  | 3300 | A | <sup>(3)</sup> | 20870 | D |  |
| Common Stock | 2023-03-02 |  | M |  | 831 | A | <sup>(3)</sup> | 21701 | D |  |
| Common Stock | 2023-03-02 |  | M |  | 1912 | A | <sup>(1)</sup> | 23613 | D |  |
| Common Stock | 2023-03-02 |  | M |  | 1445 | A | <sup>(3)</sup> | 25058 | D |  |
| Common Stock | 2023-03-02 |  | M |  | 727 | A | <sup>(3)</sup> | 25785 | D |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Restricted Stock Units | <sup>(1)</sup> | 2023-03-01 |  | M |  |  | 7523 | <sup>(4)</sup> | <sup>(4)</sup> | Common Stock | 7523 | $0 | 15048 | D |  |
| Restricted Stock Units | <sup>(1)</sup> | 2023-03-02 |  | M |  |  | 1941 | <sup>(5)</sup> | <sup>(5)</sup> | Common Stock | 1941 | $0 | 0 | D |  |
| Performance Stock Units | <sup>(3)</sup> | 2023-03-02 |  | M |  |  | 3300 | <sup>(6)</sup> | <sup>(6)</sup> | Common Stock | 3300 | $0 | 0 | D |  |
| Performance Stock Units | <sup>(3)</sup> | 2023-03-02 |  | M |  |  | 831 | <sup>(7)</sup> | <sup>(7)</sup> | Common Stock | 831 | $0 | 0 | D |  |
| Restricted Stock Units | <sup>(1)</sup> | 2023-03-02 |  | M |  |  | 1912 | <sup>(8)</sup> | <sup>(8)</sup> | Common Stock | 1912 | $0 | 1912 | D |  |
| Performance Stock Units | <sup>(3)</sup> | 2023-03-02 |  | M |  |  | 1445 | <sup>(9)</sup> | <sup>(9)</sup> | Common Stock | 1445 | $0 | 1446 | D |  |
| Performance Stock Units | <sup>(10)</sup> | 2023-03-02 |  | A |  | 1457<sup>(11)</sup> |  | <sup>(12)</sup> | <sup>(12)</sup> | Common Stock | 1457 | $0 | 1457 | D |  |
| Performance Stock Units | <sup>(3)</sup> | 2023-03-02 |  | M |  |  | 727 | <sup>(13)</sup> | <sup>(13)</sup> | Common Stock | 727 | $0 | 730 | D |  |

---

### Footnotes:

(1) Restricted stock units convert to shares of TDOC common stock on a one-for-one basis.

(2) Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's restricted stock unit awards.

(3) Performance stock units convert to shares of TDOC common stock on a one-for-one basis.

(4) On March 1, 2022, the reporting person was granted 22,571 restricted stock units, vesting one-third on the first anniversary of the grant date, with the remainder vesting in eight substantially equal quarterly installments thereafter.

(5) On March 2, 2020, the reporting person was granted 5,824 restricted stock units, vesting in three substantially equal annual installments beginning on the first anniversary of the grant date.

(6) On March 2, 2021, the reporting person earned 9,900 performance stock units, vesting in three substantially equal annual installments beginning on March 2, 2021.

(7) On March 2, 2022, the reporting person earned 1,661 performance stock units, vesting in two substantially equal annual installments beginning on March 2, 2022.

(8) On March 2, 2021, the reporting person was granted 5,736 restricted stock units, vesting in three substantially equal annual installments beginning on the first anniversary of the grant date.

(9) On March 2, 2022, the reporting person earned 4,337 performance stock units, vesting in three substantially equal annual installments beginning on March 2, 2022.

(10) Each performance stock unit represents a contingent right to receive one share of TDOC common stock.

(11) Performance award amount determined based on metrics in respect of the issuer's financial results over a two-year performance period ending in 2022.

(12) The performance stock units vest in two substantially equal annual installments beginning on March 2, 2023.

(13) On March 2, 2023, the reporting person earned 1,457 performance stock units, vesting in two substantially equal annual installments beginning on March 2, 2023.

**Signature:** /s/ Adam C. Vandervoort  
**Date:** 2023-03-03

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**